- Conditions
- Asthma
- Interventions
- Benralizumab
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eosinophilic Asthma
- Interventions
- ICS-LABA, benralizumab, Placebo for Benralizumab
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
- Interventions
- Dexpramipexole Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Areteia Therapeutics
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 1,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 89
- States / cities
- Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
- Conditions
- Asthma; Eosinophilic, Asthma
- Interventions
- Lipopolysaccharides
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 99 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Severe Eosinophilic Asthma, Nasal Polyps
- Interventions
- FASENRA(benralizumab)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more
- Conditions
- Asthma
- Interventions
- Mepolizumab 100mg, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 13
- States / cities
- Long Beach, California • Riverside, California • Denver, Colorado + 10 more
- Conditions
- Asthma
- Interventions
- TEV-53275 Dose A, TEV-53275 Dose B, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 77
- States / cities
- Hoover, Alabama • Peoria, Arizona • Phoenix, Arizona + 62 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Dexpramipexole Dihydrochloride
- Drug
- Lead sponsor
- Areteia Therapeutics
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
- Conditions
- Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
- Interventions
- Budesonide-albuterol, Benralizumab
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Skokie, Illinois
- Conditions
- Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
- Interventions
- Benralizumab 30 mg, Matched placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 15
- States / cities
- Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
- Conditions
- Asthma
- Interventions
- mepolizumab
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Eosinophils, Asthma
- Interventions
- reslizumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Huntington Beach, California + 31 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more
- Conditions
- Asthma
- Interventions
- Mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • Cincinnati, Ohio + 1 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Etokimab, Placebo
- Biological · Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- NIOX MINO® Instrument (09-1100)
- Device
- Lead sponsor
- Aerocrine AB
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Sanford, North Carolina
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Interventions
- Benralizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet
- Drug
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- Depemokimab
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Brooksville, Florida • Plantation, Florida • Kansas City, Kansas + 6 more